X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs DISHMAN PHARMA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB DISHMAN PHARMA DR. REDDYS LAB/
DISHMAN PHARMA
 
P/E (TTM) x 26.4 25.1 105.3% View Chart
P/BV x 3.3 3.3 97.3% View Chart
Dividend Yield % 0.8 0.7 121.8%  

Financials

 DR. REDDYS LAB   DISHMAN PHARMA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
DISHMAN PHARMA
Mar-16
DR. REDDYS LAB/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,788374 744.7%   
Low Rs1,902129 1,475.3%   
Sales per share (Unadj.) Rs860.8197.8 435.2%  
Earnings per share (Unadj.) Rs57.121.2 269.1%  
Cash flow per share (Unadj.) Rs122.034.7 351.3%  
Dividends per share (Unadj.) Rs20.002.00 1,000.0%  
Dividend yield (eoy) %0.90.8 107.3%  
Book value per share (Unadj.) Rs757.7179.9 421.2%  
Shares outstanding (eoy) m165.9180.69 205.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.71.3 214.1%   
Avg P/E ratio x41.111.9 346.2%  
P/CF ratio (eoy) x19.27.2 265.2%  
Price / Book Value ratio x3.11.4 221.2%  
Dividend payout %35.09.4 371.6%   
Avg Mkt Cap Rs m389,03420,306 1,915.9%   
No. of employees `00023.50.8 2,837.6%   
Total wages/salary Rs m32,1495,355 600.4%   
Avg. sales/employee Rs Th6,070.819,252.7 31.5%   
Avg. wages/employee Rs Th1,366.66,459.5 21.2%   
Avg. net profit/employee Rs Th402.52,064.1 19.5%   
INCOME DATA
Net Sales Rs m142,81015,961 894.8%  
Other income Rs m1,552265 584.8%   
Total revenues Rs m144,36216,226 889.7%   
Gross profit Rs m23,5124,103 573.0%  
Depreciation Rs m10,7721,091 987.7%   
Interest Rs m788944 83.4%   
Profit before tax Rs m13,5042,334 578.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m3441 31,272.7%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,380624 702.4%   
Profit after tax Rs m9,4681,711 553.3%  
Gross profit margin %16.525.7 64.0%  
Effective tax rate %32.426.7 121.4%   
Net profit margin %6.610.7 61.8%  
BALANCE SHEET DATA
Current assets Rs m104,98411,018 952.8%   
Current liabilities Rs m68,9389,517 724.4%   
Net working cap to sales %25.29.4 268.4%  
Current ratio x1.51.2 131.5%  
Inventory Days Days74110 67.3%  
Debtors Days Days10435 297.3%  
Net fixed assets Rs m104,38516,304 640.2%   
Share capital Rs m830161 514.3%   
"Free" reserves Rs m124,88612,907 967.6%   
Net worth Rs m125,71614,516 866.1%   
Long term debt Rs m25,0894,189 598.9%   
Total assets Rs m225,44329,805 756.4%  
Interest coverage x18.13.5 522.5%   
Debt to equity ratio x0.20.3 69.1%  
Sales to assets ratio x0.60.5 118.3%   
Return on assets %4.58.9 51.1%  
Return on equity %7.511.8 63.9%  
Return on capital %9.717.5 55.4%  
Exports to sales %024.8 0.0%   
Imports to sales %03.7 0.0%   
Exports (fob) Rs mNA3,956 0.0%   
Imports (cif) Rs mNA596 0.0%   
Fx inflow Rs m72,6234,952 1,466.7%   
Fx outflow Rs m18,916697 2,714.7%   
Net fx Rs m53,7074,255 1,262.3%   
CASH FLOW
From Operations Rs m18,0302,786 647.1%  
From Investments Rs m-14,883-1,529 973.4%  
From Financial Activity Rs m-4,440-941 471.8%  
Net Cashflow Rs m-1,236316 -390.6%  

Share Holding

Indian Promoters % 25.5 61.4 41.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.4 3.7 145.9%  
FIIs % 35.3 12.7 278.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 22.1 69.2%  
Shareholders   75,885 46,261 164.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   ELDER PHARMA  FDC LTD.  SUN PHARMA  STRIDES PHARMA SCIENCE  TTK HEALTHCARE  

Compare DR. REDDYS LAB With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Nov 16, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB - AUROBINDO PHARMA COMPARISON

COMPARE DR. REDDYS LAB WITH

MARKET STATS